News about Industrial talks

UK MHRA Updates Safety Information on Semaglutide Over Rare NAION Vision Risk

UK MHRA flags a very rare risk of NAION linked to semaglutide, urging patients to seek immediate medical attention for sudden changes in vision.

Industrial talks | 07/02/2026 | By News Bureau |  661

Entod Pharmaceuticals Backs Global Push to Prevent Childhood Blindness at UK House of Lords

Entod Pharmaceuticals representatives participate in global discussions at the UK House of Lords to advance prevention-led strategies against childhood blindness, with a focus on ROP screening in India.

Industrial talks | 05/02/2026 | By News Bureau |  163

Sanofi Announces Euro 1 Billion Share Buyback Programme for 2026

R&D-driven biopharma major Sanofi to repurchase shares worth up to Euro 1 billion between February and December 2026, reinforcing its capital allocation strategy and long-term growth outlook.

Industrial talks | 04/02/2026 | By News Bureau |  519

AstraZeneca and Daiichi Sankyo's Datroway Receives FDA Priority Review for First-Line Metastatic TNBC Treatment

The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.

Industrial talks | 04/02/2026 | By News Bureau |  232

Union Budget Boosts Pharma with Biopharma Shakti with Outlay of INR 10,000 Crore

Union Finance Minister Nirmala Sitharaman unveiled multiple initiatives for pharma and life sciences in budget 2026–27, including Biopharma Shakti, NIPER expansion, CDSCO strengthening and new investments, to position India as a global biopharma hub.

Industrial talks | 01/02/2026 | By News Bureau |  334

Alvotech Reaches Global Settlement on Eylea Biosimilar

The settlement enables Alvotech and its partners to launch the biosimilar from January 1, 2026 in the UK and Canada, from May 1, 2026 in the EEA and other markets outside the US, and in Japan from May 2026 for select indications, expanding to all approved indications from November 1, 2026.

Industrial talks | 30/01/2026 | By News Bureau |  323

India's Pharma Industry Clocks INR 4.72 Lakh Crore Turnover in FY25: Economic Survey

India’s pharmaceutical industry delivered a strong performance in the financial year 2024–25, recording a total turnover of INR 4.72 lakh crore, according to the latest Economic Survey. The figures highlight the sector’s resilience and its growing role as a key contributor to India’s economy and global healthcare supply chain.

Industrial talks | 29/01/2026 | By Darshana |  2115

Bayer to Showcase Low-Dose MRI Contrast Innovation at ECR 2026

Bayer brings next-generation contrast agents and smart radiology solutions to ECR 2026, spotlighting progress in low-dose MRI imaging and clinical innovation.

Industrial talks | 28/01/2026 | By News Bureau |  563

EU Trade Pact Set to Boost Indian Pharma and Medical Device Exports

The recently finalised India–European Union Free Trade Agreement (FTA) is expected to significantly expand opportunities for India’s pharmaceutical and medical technology sectors by opening access to a USD 572 billion European healthcare market, Union Health Minister J.P. Nadda said.

Industrial talks | 28/01/2026 | By Darshana |  155

Pharma Leaders Outline Key Expectations Ahead of Union Budget 2026

Pharma industry leaders are urging the government to simplify GST on essential medicines, improve ease of doing business, enable easier access to long-term capital and provide greater policy clarity, amid more, in the upcoming Union Budget 2026.

Industrial talks | 28/01/2026 | By News Bureau |  487